Viruses have learned to modulate host functions to their own benefit.
ENYO Pharma’s founders have deciphered virus-host interactions and built viral based structural tools and platform enabling innovative drug discovery programs on many intracellular host targets yet untapped by pharma’s.
ENYO Pharma is currently focusing on virology with two leading programs – chronic hepatitis B and flu. Host-oriented ENYO Pharma’s drugs are also opening perspectives for a wide range of other therapeutic areas e.g. antibiotics and oncology.